Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUTACETUX: Skin Toxicity and Efficacy of Cetuximab in Metastatic Colon Cancer
NCT01292356Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- Dec 2010
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by CHU de Poitiers. Started Dec 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01292356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292356.